Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Advanced Biomed Inc. (ADVB)

Advanced Biomed agrees to sell Taiwan R&D unit for US$490,000

Neutral Impact 3 of 5 m&a Written later

Advanced Biomed Inc. agreed on June 30, 2026 to sell 100% of Advanced Biomed Inc. (Taiwan), its wholly-owned subsidiary that runs its biomedical research and development, to an unrelated third party. The filing says the company will keep its remaining businesses, including AI-focused operations through Acellent Technologies (Hong Kong) Co. Limited, and the closing is expected within three months.

Key points

  • Aggregate purchase price is US$490,000, subject to the agreement's terms and conditions.
  • The Taiwan Subsidiary conducts the company's biomedical R&D, including the A+PerfusC 3D cell culture platform.
  • Closing is expected within three months of the agreement date; the filing lists closing conditions as a risk factor.
  • The full Share Purchase Agreement is filed as Exhibit 10.1.

The filing

CompanyAdvanced Biomed Inc. (ADVB)
Form8-K, current report
Filed with the SECJun 30, 2026, 4:34 PM ET
Accession number0001213900-26-073735

Items reported: 1.01 Material Definitive Agreement

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.